Recap: Aspira Womens Health Q2 Earnings

Shares of Aspira Womens Health AWH rose 7.6% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 50.00% year over year to ($0.06), which were in line with the estimate of ($0.06).

Revenue of $1,799,000 up by 141.15% from the same period last year, which beat the estimate of $1,610,000.

Outlook

Aspira Womens Health hasn't issued any earnings guidance for the time being.

Aspira Womens Health hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Aug 12, 2021

Time: 04:30 PM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/46313/indexl.html

Recent Stock Performance

Company's 52-week high was at $10.54

Company's 52-week low was at $2.47

Price action over last quarter: down 13.89%

Company Profile

Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!